Pharmaceutical filing citing Epilepsia paper — Filana Therapeutics, 2026-07-29
Filana TherapeuticsFilana TherapeuticsNASDAQ FLNA
Filings SEC · Quote Yahoo cited a paper published in Epilepsia in its regulatory filing with the U.S. Securities and Exchange CommissionU.S. Securities and Exchange Commission
Regulator · Website. The company read the manner in which it wrote the paper and the actual scope presented in the paper in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.
The disclosure wrote the paper like this in the press release
When a U.S. listed company has something to inform its shareholders, the form it files with the Securities and Exchange Commission is called 8-K. The item numbers of the document filed by Filana Therapeutics on 2026-07-29 were 2.02 Earnings Release · 9.01 Financial Statements and Exhibits. The company cited a paper published in Epilepsia in the press release attached to it. If the sentence citing the paper is translated verbatim, it reads as follows.
Participation in the TSC World Conference this week will keep us connected and prepared for future development of simufilam as the regulatory process continues.” Scientific Presentations and Publications Publication of Eilat XVIII Proceedings in Epilepsia : Peer-reviewed proceedings of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII) have been published in Epilepsia .
The reader should first check where the company placed the paper in the press release. Next, they should determine whether the paper supports the entire company claim or only a part of it. To answer the latter question, one must read the full paper. This article, which has only read the abstract, cannot provide an answer to that.
The scope of the paper discussed in the abstract is limited to this.
The paper's title is Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices ( EILAT XVIII ). I. Treatments in preclinical and early clinical development and it was published in Epilepsia on July 18, 2026. The authors are affiliated with Hebrew University of Jerusalem, Jerusalem Institute for Israel Studies, Oslo University Hospital, and OsloMet – Oslo Metropolitan University. The summary at the beginning of the paper is called abstract. This article has read only up to this point. This paragraph was rewritten by a person after filtering a draft written by a machine that read the abstract, and thus it is of a different quality than a full reading of the paper.
This article is not a research paper but a report from an international academic conference on a new epilepsy treatment. It summarizes eight therapies in preclinical or early clinical stages presented at this 34th consecutive conference. One of them is a substance targeting a rare epilepsy syndrome by regulating potassium channels. This article organizes which stage each therapy is in. It is not an article judging effectiveness.
What the abstract does not answer remains in the full text and appendices. This article, which has not gone beyond the abstract, leaves gaps as they are. Readers should compare the two citations above to determine which sentence in the abstract corresponds to the citation provided by the company.
One month later, the stock price was within the middle half of the sample.
The remaining return after subtracting the portion that moves with the overall market is called excess return. The date is written as trading day, counting only the days the stock market is open. In terms of the calendar, 20 trading days are about a month. The excess return for the day of the regulatory filing and the following month are listed in the table below.
| Period | Excess return relative to the market | Meaning |
|---|---|---|
| Five trading days before the filing | −11.4% | The extent of movement before the filing |
| On the day of the filing | −0.3% | On the filing day or the first trading day after |
| Accumulated over +1 to +5 trading days | +6.4% | One week |
| +1 to +20 trading days cumulative | +2.0% | One month |
A bundle of past cases of the same type is called a sample. The position counted from the bottom is expressed as a percentile. The one-month excess return of +2.0% in this case is within the bottom 68% of the 142 samples and is within the lower half.
| Sample scale (20 trading days) | Tenth from the bottom | Fourth from the bottom | median | top 25% | top 10% | This case |
|---|---|---|---|---|---|---|
| Excess return | −31.9% | −20.1% | −7.4% | +5.5% | +19.5% | +2.0% |
Half of the sample falls between the two central marks in the chart. One checks from the chart whether this case lies inside or outside. The sample collects cases where U.S. listed companies wrote papers in 8-K over the past ten years. The company itself is excluded from the sample. The numbers written here are past facts, not rules applicable to the next case.
There is one additional case where the same company wrote a paper in 8-K, so it is placed together in the table below.
| Disclosure date | the journal of the paper | a month's excess return |
|---|---|---|
| 2026-05-07 | Epilepsia | −0.8% |
after the filing, the company issued such documents
after the filing date, the company issued three 8-K filings. Only the item numbers are listed here. In 8-K filings without titles, the item numbers indicate the type of content. Whether it was an earnings announcement or a contract can be determined by the number. The specifics of what occurred are read in the original text of each link.
- 2026-09-18 8-K Item 3.01 —
What This Article Did Not Answer
This article, which only read abstracts, could not answer how the paper re-examined what and showed up to where through what methods. How many times the paper cited by the company was cited afterward can be re-confirmed through the citation count on OpenAlexOpenAlex
Data source · Website. The next thing to look at is whether the company's next 8-K again cites the same paper.
Explanation of Terms
- 8-K
- A voluntary report submitted to the Securities and Exchange Commission when a U.S. listed company has something to inform its shareholders. It is categorized by item numbers such as earnings, contracts, and executive changes. All the events in this article come from this document.
- Excess return
- The remainder after subtracting the overall market return from the stock return. It is used to see the movement unique to the company by removing the portion attributable to the market as a whole.
- Trading day
- A date counting only the days the stock market is open. Since weekends and holidays are excluded, 20 trading days correspond to about a month on the calendar.
- Sample and percentile
- A bundle of past cases of the same type is a sample, and the position from the bottom is expressed as a percentile. A percentile of 10 means that nine out of ten cases performed better than this case.
- Abstract
- A summary placed at the beginning of a paper. The author writes in a few sentences what was done, how it was done, and what results were obtained. Without reading the full text, one cannot know the details and limitations of the method.